
Pharmaceutical giant Eli Lilly and Spanish dermatology company Almirall have come together to develop a treatment for atopic dermatitis, also known as atopic eczema.
The partnership is now ready to publicize more partial results from a global phase III program, this time demonstrating significant improvements in disease severity, a joint press release reports.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app